Cheri E Klein

No ORCID on file · 4 papers in corpus · active 2018-2020

Study types

  • article 3
  • review 1

Condition tags

  • endometriosis 3
review 2020
Clinical pharmacokinetics ·doi:10.1007/s40262-019-00840-7

The clinical pharmacology of elagolix was extensively evaluated in clinical studies in healthy subjects and in women with endometriosis. Elagolix pharmacokinetics (PK) show significant population variability, however they are minimally affe…

article 2019
The Journal of clinical endocrinology and metabolism ·doi:10.1210/clinem/dgz086

CONTEXT: Elagolix is an oral gonadotropin-releasing hormone (GnRH) antagonist recently approved for the treatment of endometriosis-associated pain and being developed for heavy menstrual bleeding associated with uterine fibroids. OBJECTIVE:…

article 2018
Clinical pharmacology in drug development ·doi:10.1002/cpdd.640

The aim of these studies was to assess the safety and pharmacokinetics of elagolix, an oral nonpeptide gonadotropin-releasing hormone antagonist following oral administration in women with renal or hepatic impairment. Two phase 1 studies we…

article 2018
Clinical pharmacokinetics ·doi:10.1007/s40262-018-0629-6